
Thursday, April 17, 2025 6:32:34 PM
6, 12, 2023 —
SEC charged investment adviser Sabby Management LLC & managing partner,Hal D. Mintz,w/ fraud in connection w/ a long running scheme involving misrepresentations & violations of rules for short selling & order making, + other violative trading, that generated $2M + in illegal profits.
From at least March 2017-May 2019 Sabby|Mintz repeatedly circumvented trading rules to conduct unlawful trades in the stock of 10 PUBLIC COMPANIES. Sabby |Mintz engaged in illegal “naked short selling” by intentionally|improperly placing short sales when they knew or were reckless in not knowing that they had not borrowed or located the shares, & then failed to make timely delivery of the shares. The purpose was to earn profits they could not have gained by legal trading. https://www.sec.gov/news/press-release/2023-107
".....me too..... but for stocks......"


Recent HMBL News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 07/09/2025 03:00:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/05/2025 09:30:06 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/09/2025 09:31:33 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 04/30/2025 08:47:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/18/2025 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 08:34:05 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2025 03:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2025 08:10:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 10:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 10:27:27 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/26/2024 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 07:25:49 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/20/2024 02:43:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 09:05:16 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/11/2024 10:21:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 03:42:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/19/2024 09:00:38 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2024 11:14:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 04:10:18 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/11/2024 08:35:17 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/30/2024 08:40:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:53:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 08:16:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:05:13 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM